Compare Target Corporation (TGT) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Target Corporation vs Vertex Pharmaceuticals Incorporated — how do they compare? Target Corporation trades at $153.36 (market cap $70.31B), while Vertex Pharmaceuticals Incorporated trades at $514.04 (market cap $127.55B). The key difference: Vertex Pharmaceuticals Incorporated is the larger of the two by market cap, and Target Corporation pays a 3% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals — on Pluang, investors hold Target Corporation for 137 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| TGT | VRTX | |
|---|---|---|
Market Cap | $70.31B | $127.55B |
Volume | 4,164,999 | 1,487,944 |
Sector | Consumer Staples | Health |
52-Week High | $169.90 | $557.96 |
52-Week Low | $83.68 | $407.37 |
Typical Hold Time | 137 Days | 120 Days |
Enterprise Value | $83.58B | $121.68B |
Dividend Yield | 3% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Target trades at $150.96, down 2.18% today, with technical indicators showing bearish momentum. The company maintains solid fundamentals with a P/E of 16.05 and strong profitability metrics including 26.41% ROE. Recent earnings have consistently beaten expectations, with Q2 2026 EPS of $4.11 significantly exceeding the $2.35 forecast. The company's holiday price-cutting strategy aims to capture market share amid competitive retail pressures.
Target presents a mixed outlook with 46.7% analyst buy ratings and a $167.18 consensus target suggesting 10.8% upside. Strong cash flow generation and dividend sustainability support the investment case, though margin pressures from aggressive pricing and retail competition pose near-term challenges. The stock's current valuation appears reasonable relative to historical levels.
Vertex Pharmaceuticals (VRTX) trades at $505.64, up 0.63% with mixed technical signals showing bearish moving averages but neutral oscillators. The company maintains strong fundamentals with $12B revenue, 35% net margin, and robust cash flow. Recent positive Phase 2b data for kidney drug inaxaplin and cystic fibrosis dominance support growth. Earnings show volatility with Q1 beat but Q2 miss against expectations.
Outlook remains positive with 84% analyst buy ratings and $573.50 consensus target offering 13% upside. Key risks include clinical trial outcomes, competitive pressures, and reliance on cystic fibrosis portfolio. The stock presents growth potential through pipeline expansion but faces sector volatility and execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Target Corporation
With 1,926 stores (as of the end of fiscal 2021), Target is a leading American general merchandise retailer, offering a variety of products across several categories, including beauty and household essentials (26% of fiscal 2021 sales), food and beverage (19%), home furnishings and décor (19%), hardlines (18%), and apparel and accessories (17%). Most of Target's stores are large, averaging more than 125,000 square feet. The company has a significant e-commerce presence, deriving around 19% of sales from the channel (up from about 9% in fiscal 2019, before the pandemic). In addition to its namesake stores, Target owns Shipt, an online same-day delivery platform. After it exited Canada in 2015, virtually all of Target's revenue is generated from the United States.
Read more on TGT →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
